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Abstract Regio- and stereoselective methods for the synthesis of 6′-
trifluoro(trichloro)methyl substituted spiro[acenaphthylene-1,11′-
chromeno[3,4-a](thia)pyrrolizidin]-2-ones and spiro[acenaphthylene-
1,12′-chromeno[3,4-a]indolizidin]-2-ones have been developed based
on the three-component reaction of 3-nitro-2-trifluoro(trichloro)meth-
yl-2H-chromenes with azomethine ylides generated in situ from ace-
naphthenequinone and cyclic -amino acids. The cycloaddition pro-
ceeds under mild conditions in ethanol or DMSO, and only endo-isomers
of the products with cis-arrangement of nitro and trifluoromethyl
groups are formed. The relative configuration of cycloadducts is reliably
confirmed by X-ray diffraction analysis and by 2D NOESY spectroscopy.
Key words 3-nitro-2-trifluoro(trichloro)methyl-2H-chromenes, 1,3-
dipolar cycloaddition, azomethine ylides, acenaphthenequinone, cyclic
-amino acids
Diversity-oriented synthesis (DOS) of small molecules
followed by screening of these molecules for their ability to
modulate a biological pathway in cells or organisms is one
of the most effective and dynamically developing approach-
es to modern drug discovery. In the last decade, special at-
tention has been paid to increasing the structural and func-
tional diversity in the construction of collections of small
molecules.1
One DOS approach involves the creation of compound
libraries based on privileged molecular scaffolds, ubiqui-
tous in clinically significant bioactive natural products, fol-
lowed by an increase in the scaffold diversity about the
privileged skeleton. From this point of view, 3-nitro-2-tri-
fluoro(trichloro)methyl-2H-chromenes2 are suitable start-
ing compounds for privileged-substructure-based DOS. The
molecular cores of chromenes and chromanes are present
in the skeleta of numerous natural and synthetic bioactive
compounds.2,3 For example, 3-nitro-2-trifluoromethyl-2H-
chromene (TIM-38) has been shown to be a P2Y6 receptor
inhibitor and a promising anti-inflammatory agent (Figure
1).4a 6-Bromo-8-ethoxy-3-nitro-2H-chromene (BENC-511)
exhibits antitumor activity against various cancer cell lines
due to the inhibition of phosphoinositide 3-kinase.4b It was
recently found that 6-CF3-spiro[chromenopyrrolidine-1,3′-
oxindoles] (A) have a pronounced cytotoxic activity against
HeLa human cervical cancer cells.4c Glabridin, an isoflavane,
isolated from the roots of Glycyrrhiza glabra, is a drug can-
didate for memory improvement.4d
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nitro-2H-chromenes actively react with nucleophiles and
1,3-dipoles. The replacement of the hydrogen atom in the
2-position with a more bulky trifluoro(trichloro)methyl
group with a pronounced negative inductive effect leads to
an increase in the stereoselectivity of nucleophilic addition
and cycloaddition at the C=C bond.2 It should be noted that
nitrochromenes 1 (see Scheme 1) are readily available and
can be obtained from 1-nitro-3,3,3-trifluoro(trichloro)-1-
nitroprop-1-enes and the corresponding salicylaldehydes
in good yield.5
On the other hand, the trifluoromethyl group is a phar-
macophore fragment that is present in a wide variety of
drugs due to its increased lipophilicity and greater strength
of the C–F bond compared to the C–H bond.6 Among CCl3-
containing organic molecules, compounds with GLI1-inhib-
itory, anthelmintic, antiplasmodial and 5-HT-inhibitory af-
fects are known.7
1,3-Dipolar cycloaddition (1,3-DC) of stabilized azome-
thine ylides to activated alkenes is the shortest and the
most efficient route to construction of the spiropyrro-
li(zi)dine and spiroindolizidine ring systems in a single re-
action step.8 This procedural-, atom-, and stage-economic
(PASE)9 strategy allows the creation of large libraries of
such spiro-heterocycles from available reagents using a
simple methodology based on intermolecular three-com-
ponent reactions.10 Intensive developments in this direc-
tion have led to the production of new representatives of
spiropyrrolizidines with anticancer11a (B), antimicrobial11b
(C), and AChE-inhibitory11c (D) activities, as depicted in Fig-
ure 2. Pyrrolizidine and indolizidine scaffolds are ubiqui-
tous in natural compounds. In particular, pteropodine is an
alkaloid isolated from Uncaria tomentosa that acts as a posi-
tive modulator of muscarinic M1 and 5-HT2 receptors and
may be involved in the improvement of impaired higher
cognitive processes.11d Moreover, pteropodine has shown a
pronounced enhancement effect on phagozytosis,11e as well
as cytostatic11f and antimutagenic11g properties and is used
in traditional medicine to cure a number of diseases (Figure
2).
The cycloaddition of stabilized azomethine ylides based
on acenaphthenequinone and -amino acids to activated
alkenes is being intensively studied.8d,e,12 This is largely due
to the fact that the spiroacenaphthylenone fragment is
present in a number of synthetic compounds that have bio-
logical properties, including antimycobacterial13a,b (D, E)
and antimalarial (F) activities.13c As was recently found, the
spiroindolizidine derivative G is capable of enhancing os-
teoblast differentiation of human stem cells (Figure 3).13d
Continuing our research aimed at studying the regio-
and stereoselectivity of reaction of 1,3-DC of azomethine
ylides with 3-nitro-2-trifluoro(trichloro)methyl-2H-
chromenes,14 in this work we report the regioselective and
diastereoselective synthesis of chromene-spiro(thia)pyr-
rolizidine and chromene-spiroindolizidine hybrids 4, 6 and
7 from nitrochromenes 1, acenaphthenequinone 2 and cy-
clic -amino acids 3 and 5 by a one-pot, three-component
[3+2]-cycloaddition approach (Scheme 1).
Diversity of substrates and reagents was provided by
varying the substituents R1 and R2 in the benzene ring of
the starting nitrochromenes, as well as the use of four cyclic
-amino acids (L-proline, L-thiaproline, L-pipecolic acid, (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid) in the
1,3-DC reaction. Diversity of pharmacophores was ensured
by the presence of chromane, spiro(thia)pyrrolizidine,
spiroindolizidine and spiroacenaphthylenone scaffolds in
the target products along with the trifluoro(tri-
chloro)methyl group at the 6′ position.
First, the three-component reaction between nitro-
chromenes 1, acenaphthenequinone 2 and (thia)proline 3
was studied. To obtain spirochromeno[3,4-a](thia)pyr-
rolizidines 4, conditions optimization for a model reaction
of nitrochromene 1a with azomethine ylide generated in
situ from acenaphthenequinone 2 and L-proline 3a was
performed (Table 1). When the reaction was carried out in
methanol or ethanol at reflux, the target product 4a was
obtained as a single endo isomer in moderate yield after 2 h,
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served (entries 1 and 3). Lowering the temperature to 55 °C
led to an increase in product yield (entries 2 and 4). At the
same temperature in isopropanol the product yield was
lower (entry 5). In acetonitrile and DMSO, the target pro-
duct was obtained even at room temperature within 24 h in
46% and 68% yield, respectively (entries 6 and 7). When THF
was used as a solvent at room temperature over 2.5 h, a
complex mixture of products was observed (entry 9). When
benzene or toluene were used as solvents, the yields of the
target product were noticeably lower (entries 10 and 11).
The best results were achieved when the reaction was
carried out in ethanol or DMSO at 55 °C (Table 1, entries 4
and 8). In both cases, the reaction was complete after 3 h
and product 4a was obtained in 77 and 75% yields, respec-
tively. Considering the ease of removal of the solvent and its
cost, we chose ethanol as the preferred solvent for the syn-
thesis of compounds 4. No other regio- or stereoisomers
were detected in the crude products by 1H NMR spectro-
scopic analysis.
Under the optimized conditions, the spirochrome-
no[3,4-a]pyrrolizidines 4a–q and spirochromeno[3,4-a]thi-
apyrrolizidines 4r–y were obtained in 36–89% yields in eth-
anol at 55 °C for 1–3.5 h using acenaphthenequinone 2, L-
proline 3a or L-thiaproline 3b and 2-CX3 substituted (X = F,
Cl) 3-nitro-2H-nitrochromenes 1 containing electron-do-
nating or electron-withdrawing groups in the benzene ring
(Table 2). Note that due to their low solubility, the target
products were isolated from the reaction mixture by filtra-
tion and purified by washing with ethanol and water.
In general, the nature of halogen and substituents R1, R2
in the starting chromene 1 has little effect on the yield of
products 4. However, introduction of electron-deficient
substituents such as Cl, Br or NO2 into the benzene ring of
the chromene reduced the reaction time to 1–2 h, while re-
actions with chromenes containing electron-donating
groups (R1, R2 = Me, OMe, OEt) under the same conditions
were complete after 3–3.5 h. 1,3-DC involving the ylide
from thiaproline was accompanied by lower yields (36–
72%). In this case, the lowest yields (39 and 36%, respective-
ly) were obtained for adducts 4v and 4w from 2-trichloro-
methyl substituted chromenes 1j and 1l.




































R1 = H, Me, MeO, Cl, Br, NO2; 
R2 = H, EtO, Cl, NO2;
X = F, Cl;







Table 1  Conditions Optimizationa
Entry Solvent Temp (°C) Time (h) Yield (%)b
1 MeOH reflux 2 55c
2 MeOH 55 2.5 67
3 EtOH reflux 2 54c
4 EtOH 55 3 77
5 i-PrOH 55 3 43
6 MeCN 25 24 46
7 DMSO 25 24 68
8 DMSO 55 3 75
9 THF 25 2.5 –d
10 PhH 55 3 57
11 PhMe 55 3 57
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In contrast to ,-unsaturated ketones and carboxylic
acid derivatives, the reactions of strongly polar nitrosty-
renes and 3-nitro-2H-chromenes with stabilized azome-
thine ylides based on cyclic carbonyl compounds and amino
acids were accompanied by the binding of a more electro-
philic -C atom of the dipolarophile with the more substi-
tuted atom of the 1,3-dipole,8 apparently due to the charge-
controlled cycloaddition. A possible reaction mechanism
involves the endo-addition of the S-shaped azomethine
ylide to nitrochromene 1 through TS-1 (see Table 2). In ad-
dition, the ylide attacks the C=C bond from the side of the
small H-2 atom, rather than from the side of the trifluoro-
methyl group. In the exo-transition state TS-2 the pyran
ring of the chromene and the (thia)proline moiety of ylide
are located one under the other, making it less favorable
due to unfavorable steric interactions (Table 2).
Next, to obtain spirochromeno[3,4-a]indolizidines 6
and 7, reactions of chromenes 1 with azomethine ylides
based on acenaphthenequinone 2 and L-pipecolic acid 5a or
(S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 5b
were studied. Due to the low solubility of both amino acids
in ethanol, DMSO was used as a solvent and a little water
was added when L-pipecolic acid was used as reagent. It
was found that these three-component reactions proceeded
at 60–70 °C within 7 or 12 h and led to the corresponding
products 6 or 7 as single isomers in 42–71% yields (Table 3).








1 1a F H H 4a CH2 3 77 14 1n Cl Cl H 4n CH2 2 82
2 1b F Me H 4b CH2 3 78 15 1o Cl Cl Cl 4o CH2 2 78
3 1c F OMe H 4c CH2 3.5 78 16 1p Cl NO2 H 4p CH2 1 79
4 1d F H OEt 4d CH2 3.5 80 17 1q Cl NO2 NO2 4q CH2 1 82
5 1e F Cl H 4e CH2 2 81 18 1a F H H 4r S 3 56
6 1f F Cl Cl 4f CH2 2 67 19 1c F OMe H 4s S 3 61
7 1g F Br OEt 4g CH2 2 81 20 1f F Cl Cl 4t S 2 72
8 1h F NO2 H 4h CH2 1 89 21 1h F NO2 H 4u S 1 66
9 1i F NO2 NO2 4i CH2 1 81 22 1j Cl H H 4v S 3 39
10 1j Cl H H 4j CH2 3 76 23 1l Cl OMe H 4w S 3 36
11 1k Cl Me H 4k CH2 3 71 24 1o Cl Cl Cl 4x S 2 65
12 1l Cl OMe H 4l CH2 3.5 75 25 1q Cl NO2 NO2 4y S 1 69
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As shown in Table 3, the donor-acceptor properties of
substituents on the chromene have little effect on the tar-
get product yield. At the same time, the yields of 6′-tri-
chloromethyl substituted spirochromeno[3,4-a]indolizi-
dines 6 were always 7–18% lower than the yields of the
corresponding CF3-substituted products.
Due to the low solubility of adducts 6 in the DMSO/H2O
mixture, most of them were isolated from the reaction mix-
ture by filtration and purified by recrystallization. Spiroad-
ducts 7, soluble in DMSO, were precipitated from the reac-
tion mixture by adding water and purified by column chro-
matography.
The IR spectra of products 4, 6 and 7 show the stretch-
ing vibrations of the carbonyl group ( = 1697–1728 cm–1)
and the NO2 group ( = 1547–1566 cm
–1, 1327–1345 cm–1).
In the 1H NMR spectra of spirochromeno[3,4-a](thia)pyr-
rolizidines 4 and spirochromeno[3,4-a]indolizidines 6 and
7 in CDCl3, the characteristic singlet of the benzylic H-11a′
proton (H-12a′ proton and H-14a′ proton in compounds 6
and 7, respectively) at  = 4.58–5.39 ppm was observed. The
signal of the H-6′ proton was manifest as quartet at  =
5.43–6.56 ppm with coupling constants 3JHF = 5.5–6.8 Hz in
the 6′-CF3 substituted compounds 4, 6, and 7 or as a singlet
at  = 5.67–6.93 ppm in the 6′-CCl3 substituted compounds
4 and 6. The H-1′ aromatic proton was shielded in all ad-
ducts by the benzene ring of acenaphthene moiety, such
that its signal is shifted upfield relative to other aromatic
protons of the chromane ring and resonates at  = 5.04–
6.88 ppm. The 19F NMR spectra of 6′-CF3 substituted com-
pounds 4, 6, and 7 contain a doublet or broad singlet due to
the trifluoromethyl group at  = 90.4–95.9 ppm. The 13C
NMR spectra of products 4, 6, and 7 exhibit a carbonyl car-
bon signal at  = 202.9–208.9 ppm and quartets due the CF3
group and the C-6′ atom are observed in the range of 121.1–
123.4 and 76.8–77.7 ppm, respectively, with coupling con-
stants 1JCF = 280.9–284.4 Hz and 
2JCF = 32.2–34.8 Hz.
The reaction of 3,6-dinitro-2-trichloromethyl-2H-
chromene 1p with the azomethine ylide based on 2 and
pipecolic acid 5a was accompanied by the elimination of
HCl and led to a mixture of the target product 6o and 2-di-
chloromethylidene derivative 8 in a 76:24 ratio (Scheme 2).
It was not possible to isolate compounds 6o and 8 in their
pure form.
In the 1H NMR spectrum of compound 8 there was no
signal for the H-6 proton, while in its 13C NMR spectrum, 21
signals of sp2-carbon atoms were observed. Moreover, the
mass spectrum of the crude product obtained in the posi-
tive ion mode ESI-HRMS showed a peak at m/z 552.0727
that corresponded to the molecular ion [8+H]+ along with
the molecular ion [6o+H]+ at m/z 588.0494. A similar out-
come has been previously observed in reactions of 2-tri-
chloromethyl substituted nitrochromenes 1 with sodium
azide15a and in the interaction of (E)-3,3,3-trichloro-1-nit-
roprop-1-ene with diaryldiazomethanes.15b The elimina-
tion of HCl is probably the main reason for the lower yields
of 6′-CCl3 products 6 compared to their 6′-CF3 analogues.
Entry Chromene X R1 R2 Product Yield (%)a Entry Chromene X R1 R2 Product Yield (%)a
1 1a F H H 6a 58 12 1m Cl H OEt 6l 49
2 1b F Me H 6b 62 13 1n Cl Cl H 6m 50
3 1c F OMe H 6c 58 14 1o Cl Cl Cl 6n 55
4 1d F H OEt 6d 56 15 1a F H H 7a 52
5 1e F Cl H 6e 62 16 1b F Me H 7b 71
6 1f F Cl Cl 6f 64 17 1c F OMe H 7c 63
7 1g F Br OEt 6g 60 18 1d F H OEt 7d 64
8 1h F NO2 H 6h 67 19 1e F H Cl 7e 62
9 1j Cl H H 6i 43 20 1f F Cl Cl 7f 68
10 1k Cl Me H 6j 44 21 1g F Br OEt 7g 58
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reaction of 2-CCl3 substituted nitrochromenes 1 with
azomethine ylide from 2 and tetrahydroisoquinoline-3-car-
boxylic acid 5b. The reaction did not proceed at 60 °C and
extensive decomposition was observed at higher tempera-
tures. This may be due to the formation of unstable 2-(di-
chloromethylidene)nitrochromenes at 70 °C.15a
The structures and relative configurations of com-
pounds 4, 6, and 7 were unambiguously confirmed by X-ray
diffraction studies of products 4a and 6g (Figures 4 and 5)
and by a 2D 1H–1H NOESY experiment for product 7g (Fi-
gure 6).
As seen in Figure 4 and Figure 5, in both molecules the
carbonyl group of the acenaphthylenone moiety and the ni-
tro group are located on opposite sides of the plane of the
condensed heterocycle, while the nitro group, CF3 group,
and hydrogen atoms H-12a′ (H-14a′ in compound 6g) and
H-6b′ are on the same side of this plane.
The 2D 1H–1H NOESY spectrum of compound 7g shows
a NOE cross-peak H-6′↔H-6b′ and no cross-peak H-6′↔H-
14a′, indicating the cis-arrangement of the H-6′ and H-6b′
protons and a trans-arrangement of the H-6′ and H-14a′
protons relative to the plane of the heterocyclic system (Fi-
gure 6). Along with this, the cross-peaks H-14a′↔H-1′ and
H-8↔H-1′ indicate the endo-configuration of adduct 7g.
Figure 6  Main correlations in the 1H–1H NOESY NMR spectrum of 
compound 7g
In summary, a simple and effective method for the syn-
thesis of novel 6′-trifluoro(trichloro)methyl substituted
spiro[acenaphthylene-1,11′-chromeno[3,4-a](thia)pyr-
rolizidin]-2-ones and spiro[acenaphthylene-1,12′-chrome-
no[3,4-a]indolizidin]-2-ones has been developed based on
a multicomponent regio- and stereoselective PASE-strategy.
Diversity of pharmacophores in the target products was en-
sured by the hybridization of biologically active scaffolds.
This approach allows libraries of hybrid heterocycles to be
obtained rapidly based on readily available 3-nitro-2-triha-
Scheme 2  Target and side products in the reaction of nitrochromene 

































Figure 4  Molecular structure of compound 4a (thermal vibration ellip-
soids of 50% probability)
Figure 5  Molecular structure of compound 6g (thermal vibration ellip-
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ry bioscreening. Further studies of the biological properties
of the obtained spirocycloadducts are planned.
IR spectra were recorded with a Shimadzu IRSpirit-T spectrometer
equipped with an ATR accessory. NMR spectra were recorded with
Bruker DRX-400 (1H, 400 MHz; 19F, 376 MHz) and Bruker Avance III-
500 (1H, 500 MHz; 19F, 471 MHz; 13C, 126 MHz) spectrometers in
CDCl3. The 2D 
1H–1H NOESY spectrum of compound 7g was acquired
on a Bruker Avance NEO (600 MHz) spectrometer with 0.3 s mixing
time. Chemical shifts () are reported in ppm relative to the internal
standard TMS (1H NMR), C6F6 (
19F NMR) and to residual signals of the
solvents ( = 77.16 ppm, 13C NMR). HRMS spectra were obtained with
a Bruker maXis Impact HD (qTOF MS) instrument. Elemental analyses
were performed with a Perkin Elmer PE 2400 automatic analyser.
Melting points were determined with an SMP40 apparatus. The start-
ing 3-nitro-2-trifluoro(trichloro)methyl-2H-chromenes 1a–q were
prepared according to described procedures.5
Synthesis of Spirochromeno[3,4-a](thia)pyrrolizidines 4; General 
Procedure
A suspension of the corresponding nitrochromene 1 (0.25 mmol),
acenaphthenequinone (46 mg, 0.25 mmol) and L-proline (38 mg, 0.33
mmol) or L-thiaproline (44 mg, 0.33 mmol) in EtOH (2 mL) was stirred
at 55 °C for the time indicated in the Table 2. Then the mixture was
cooled to r.t., the precipitate was filtered off, washed successively
with EtOH (5 × 1 mL), H2O (5 × 1 mL) and dried at 60 °C. In some cases,




Obtained according to the general procedure from 1a (61 mg) and L-
proline.
Yield: 92 mg (77%); cream powder; mp 177–178 °C (decomp.).
IR (ATR): 1714, 1581, 1553, 1497, 1340 cm–1.
1H NMR (400 MHz):  = 8.19 (d, J = 8.1 Hz, 1 H), 8.06 (d, J = 8.0 Hz, 1
H), 7.90 (d, J = 6.8 Hz, 1 H), 7.84 (t, J = 7.5 Hz, 1 H), 7.79 (d, J = 6.8 Hz, 1
H), 7.74 (t, J = 7.5 Hz, 1 H), 7.03–6.97 (m, 2 H), 6.42–6.34 (m, 1 H), 5.90
(q, J = 6.7 Hz, 1 H), 5.83 (d, J = 7.7 Hz, 1 H), 5.28 (s, 1 H), 4.61 (t, J = 6.9
Hz, 1 H), 3.17–1.67 (m, 6 H).
19F NMR (376 MHz):  = 94.4 (d, J = 6.7 Hz, CF3).
13C NMR (126 MHz):  = 203.2, 152.6, 142.8, 137.4, 132.2, 131.9,
131.0, 128.9, 128.8, 128.7, 126.6, 126.0, 123.2 (q, J = 281.8 Hz, CF3),
123.0, 122.7, 122.1, 118.7, 117.6, 96.3, 77.2, 77.1 (q, J = 33.5 Hz, C-6′),
69.6 (q, J = 2.3 Hz, C-6b′), 51.8, 49.3, 28.4, 25.1.





Obtained according to the general procedure from 1b (65 mg) and L-
proline.
Yield 97 mg (78%); grey powder; mp 172–173 °C (decomp.).
IR (ATR): 1726, 1605, 1554, 1497, 1497, 1338 cm–1.
1H NMR (400 MHz):  = 8.19 (d, J = 8.0 Hz, 1 H), 8.06 (d, J = 8.0 Hz, 1
H), 7.89 (d, J = 6.9 Hz, 1 H), 7.85 (t, J = 7.5 Hz, 1 H), 7.78 (d, J = 6.9 Hz, 1
H), 7.73 (t, J = 7.5 Hz, 1 H), 6.86 (d, J = 8.0 Hz, 1 H), 6.78 (br d, J = 8.0
Hz, 1 H), 5.83 (q, J = 6.6 Hz, 1 H), 5.52 (s, 1 H), 5.21 (s, 1 H), 4.62 (t, J =
6.8 Hz, 1 H), 3.19–1.64 (m, 6 H), 1.59 (s, 3 H).
19F NMR (376 MHz):  = 94.4 (d, J = 6.6 Hz, CF3).
13C NMR (126 MHz):  = 203.5 (C=O), 150.4, 142.8, 137.7, 132.2, 132.0
(2С), 130.9, 129.4, 128.9, 128.8, 126.5, 126.3, 123.3 (q, J = 281.8 Hz,
CF3), 122.5, 122.1, 118.3, 117.3, 96.0, 69.7 (q, J = 2.0 Hz, C-6b′), 52.2,
49.1, 28.4, 25.1, 20.4 (the signals of two carbon atoms overlap with
the signal of CDCl3).





Obtained according to the general procedure from 1c (69 mg) and L-
proline.
Yield: 100 mg (78%); pale-yellow powder; mp 158–159 °C (decomp.).
IR (ATR): 1717, 1606, 1557, 1498, 1338 cm–1.
1H NMR (400 MHz):  = 8.19 (d, J = 8.0 Hz, 1 H), 8.05 (d, J = 8.1 Hz, 1
H), 7.93 (d, J = 7.0 Hz, 1 H), 7.85 (t, J = 7.5 Hz, 1 H), 7.81 (d, J = 7.0 Hz, 1
H), 7.75 (t, J = 7.5 Hz, 1 H), 6.90 (d, J = 8.8 Hz, 1 H), 6.54 (br d, J = 8.8
Hz, 1 H), 5.74 (q, J = 6.2 Hz, 1 H), 5.27 (s, 1 H), 5.24 (s, 1 H), 4.65 (t, J =
6.2 Hz, 1 H), 3.24–1.65 (m, 9 H).
19F NMR (376 MHz):  = 94.5 (d, J = 6.2 Hz, CF3).
13C NMR (126 MHz):  = 203.3 (C=O), 154.8, 146.6, 142.8, 137.6, 132.1,
132.0, 130.9, 129.0 (2C), 128.8, 126.5, 123.2 (q, J = 280.9 Hz, CF3),
122.7, 122.3, 118.6, 115.8, 109.2, 96.6, 69.8 (q, J = 2.0 Hz, C-6b′), 54.7,
52.7, 49.2, 28.2, 25.1 (the signals of two carbon atoms overlap with
the signal of CDCl3).





Obtained according to the general procedure from 1d (72 mg) and L-
proline.
Yield: 105 mg (80%); cream powder; mp 189–190 °C (decomp.).
IR (ATR): 1720, 1589, 1549, 1489, 1475, 1332 cm–1.
1H NMR (400 MHz):  = 8.18 (d, J = 8.0 Hz, 1 H), 8.04 (d, J = 8.1 Hz, 1
H), 7.91 (d, J = 6.9 Hz, 1 H), 7.83 (t, J = 7.5 Hz, 1 H), 7.78 (d, J = 7.0 Hz, 1
H), 7.73 (t, J = 7.5 Hz, 1 H), 6.59 (d, J = 8.0 Hz, 1 H), 6.29 (t, J = 8.0 Hz, 1
H), 5.83 (q, J = 6.3 Hz, 1 H), 5.42 (d, J = 8.0 Hz, 1 H), 5.32 (s, 1 H), 4.64
(t, J = 7.5 Hz, 1 H), 4.01 (q, J = 6.8 Hz, 2 H), 3.15–1.64 (m, 6 H), 1.39 (t,
J = 6.8 Hz, 3 H).
19F NMR (376 MHz):  = 94.8 (br s, CF3).
13C NMR (126 MHz):  = 203.1 (C=O), 148.3, 143.1, 142.8, 137.6, 132.0
(2C), 131.0, 128.9, 128.8, 126.5, 123.3 (q, J = 282.0 Hz, CF3), 122.8,
122.6, 122.1, 120.1, 117.6, 113.5, 96.4, 69.7 (q, J = 2.0 Hz, C-6b′), 65.3,
52.1, 48.9, 28.0, 25.1, 14.9 (the signals of two carbon atoms overlap
with the signal of CDCl3).
HRMS (ESI): m/z [M + H]+ calcd for C28H24F3N2O5: 525.1632; found:
525.1636.SynOpen 2021, 5, 1–16
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I. B. Kutyashev et al. PaperSynOpen(1S*,6′S*,6a′S*,6b′S*,11a′R*)-2′-Chloro-6a′-nitro-6′-(trifluoro-
methyl)-6a′,6b′,7′,8′,9′,11a′-hexahydro-2H,6′H-spiro[acenaphth-
ylene-1,11′-chromeno[3,4-a]pyrrolizin]-2-one (4e)
Obtained according to the general procedure from 1e (70 mg) and L-
proline.
Yield: 104 mg (81%); beige powder; mp 183–184 °C (decomp.).
IR (ATR): 1722, 1605, 1557, 1481, 1468, 1336 cm–1.
1H NMR (400 MHz):  = 8.22 (d, J = 8.0 Hz, 1 H), 8.12–8.05 (m, 1 H),
7.89–7.84 (m, 2 H), 7.82 (d, J = 7.0 Hz, 1 H), 7.76 (t, J = 7.5 Hz, 1 H),
6.54 (dd, J = 8.8, 2.0 Hz, 1 H), 6.93 (d, J = 8.8 Hz, 1 H), 5.91 (q, J = 6.6 Hz,
1 H), 5.73 (d, J = 2.0 Hz, 1 H), 5.17 (s, 1 H), 4.60 (t, J = 7.1 Hz, 1 H),
3.11–1.66 (m, 6 H).
19F NMR (376 MHz):  = 94.2 (d, J = 6.6 Hz, CF3).
13C NMR (126 MHz):  = 203.2 (C=O), 151.0, 142.8, 136.8, 132.4, 131.6,
130.9, 129.1, 128.9 (2С), 127.9, 126.9, 125.9, 123.0 (q, J = 281.6 Hz,
CF3), 122.9, 122.0, 120.2, 119.0, 96.3, 77.1, 76.9 (q, J = 33.6 Hz, C-6′),
69.5 (q, J = 2.4 Hz, C-6b′), 51.5, 49.3, 28.5, 25.1.





Obtained according to the general procedure from 1f (79 mg) and L-
proline.
Yield 90 mg (67%); cream powder; mp 179–180 °C (decomp.).
IR (ATR): 1719, 1605, 1557, 1461, 1432, 1411, 1338 cm–1.
1H NMR (400 MHz):  = 8.22 (d, J = 7.9 Hz, 1 H), 8.14–8.05 (m, 1 H),
7.91–7.81 (m, 3 H), 7.78 (t, J = 7.5 Hz, 1 H), 7.09 (s, 1 H), 5.95 (q, J = 5.8
Hz, 1 H), 5.66 (s, 1 H), 5.18 (s, 1 H), 4.60 (t, J = 6.7 Hz, 1 H), 3.10–1.66
(m, 6 H).
19F NMR (376 MHz):  = 94.2 (d, J = 5.8 Hz, CF3).
13C NMR (126 MHz):  = 203.0 (C=O), 147.2, 142.7, 136.6, 132.5, 131.5,
131.0, 129.4, 129.1, 129.0, 127.7, 127.0, 124.3, 124.0, 123.1, 122.8 (q,
J = 281.7 Hz, CF3), 122.0, 121.7, 95.0, 77.3 (q, J = 33.9 Hz, C-6′), 77.0,
69.5 (q, J = 2.0 Hz, C-6b′), 51.7, 49.1, 28.5, 25.1.





Obtained according to the general procedure from 1g (92 mg) and L-
proline.
Yield: 123 mg (81%); cream powder; mp 205–206 °C (decomp.).
IR (ATR): 1709, 1603, 1557, 1484, 1469, 1339 cm–1.
1H NMR (400 MHz):  = 8.21 (d, J = 8.0 Hz, 1 H), 8.07 (d, J = 8.0 Hz, 1
H), 7.88 (d, J = 6.9 Hz, 1 H), 7.84 (t, J = 7.5 Hz, 1 H), 7.81 (d, J = 6.9 Hz, 1
H), 7.76 (t, J = 7.5 Hz, 1 H), 6.69 (s, 1 H), 5.82 (q, J = 6.5 Hz, 1 H), 5.46 (s,
1 H), 5.19 (s, 1 H), 4.63 (t, J = 7.1 Hz, 1 H), 3.98 (q, J = 6.9 Hz, 2 H),
3.08–1.65 (m, 6 H), 1.40 (t, J = 6.9 Hz, 3 H).
19F NMR (376 MHz):  = 94.6 (br s, CF3).
13C NMR (126 MHz):  = 203.3 (C=O), 149.0, 142.7, 141.8, 137.1, 132.3,
131.8, 130.9, 129.0, 128.9, 126.7, 123.0 (q, J = 282.1 Hz, CF3), 122.7,
122.0, 121.4, 120.2, 116.3, 115.0, 95.4, 77.0 (q, J = 34.4 Hz, C-6′), 69.7
(q, J = 1.8 Hz, C-6b′), 65.4, 51.9, 48.8, 28.1, 25.1, 14.7 (the signal of one
carbon atom overlaps with the signal of CDCl3).





Obtained according to the general procedure from 1h (73 mg) and L-
proline.
Yield: 117 mg (89%); beige powder; mp 190–191 °C (decomp.).
IR (ATR): 1706, 1582, 1562, 1524, 1482, 1339, 1329 cm–1.
1H NMR (400 MHz):  = 8.24 (d, J = 7.8 Hz, 1 H), 8.14 (d, J = 8.0 Hz, 1
H), 7.94–7.85 (m, 4 H), 7.74 (t, J = 7.5 Hz, 1 H), 7.12 (d, J = 9.0 Hz, 1 H),
6.67 (d, J = 2.1 Hz, 1 H), 6.12 (q, J = 6.2 Hz, 1 H), 5.14 (s, 1 H), 4.61 (t, J =
7.4 Hz, 1 H), 3.09–1.70 (m, 6 H).
19F NMR (376 MHz):  = 93.6 (d, J = 6.2 Hz, CF3).
13C NMR (126 MHz):  = 203.5 (C=O), 156.8, 142.9, 142.7, 136.3, 132.9,
131.3, 131.1, 129.2, 129.1, 127.3, 124.6, 123.1, 122.7 (q, J = 281.5 Hz,
CF3), 122.4, 122.1, 119.2, 118.4, 93.7, 76.8 (q, J = 33.8 Hz, C-6′), 69.5 (q,
J = 2.0 Hz, C-6b′), 51.4, 49.4, 29.0, 25.1 (the signal of one carbon atom
overlaps with the signal of CDCl3).





Obtained according to the general procedure from 1i (84 mg) and L-
proline.
Yield: 115 mg (81%); cream powder; mp 178–179 °C (decomp.).
IR (ATR): 1709, 1599, 1557, 1548, 1467, 1363, 1339 cm–1.
1H NMR (400 MHz):  = 8.55 (d, J = 2.4 Hz, 1 H), 8.27 (dd, J = 7.8, 1.0
Hz, 1 H), 8.17 (d, J = 8.2 Hz, 1 H), 7.93 (dd, J = 8.2, 7.2 Hz, 1 H), 7.86 (d,
J = 7.0 Hz, 1 H), 7.82–7.74 (m, 2 H), 6.88 (d, J = 2.4 Hz, 1 H), 6.31 (q, J =
5.9 Hz, 1 H), 5.13 (s, 1 H), 4.59 (t, J = 7.5 Hz, 1 H), 3.00–1.71 (m, 6 H).
19F NMR (376 MHz):  = 93.3 (d, J = 5.9 Hz, CF3).
13C NMR (126 MHz):  = 203.2 (C=O), 150.2, 142.9, 141.1, 138.6, 135.7,
133.2, 131.2, 131.0, 129.4, 129.2, 127.6, 125.5, 123.5, 123.3, 122.1 (q,
J = 282.1 Hz, CF3), 122.0, 121.0, 92.1, 77.5, 77.2 (q, J = 34.8 Hz, C-6′),
69.4 (q, J = 2.5 Hz, C-6b′), 51.1, 49.2, 29.1, 25.1.





Obtained according to the general procedure from 1j (74 mg) and L-
proline.
Yield: 100 mg (76%); beige powder; mp 169–170 °C (decomp.).
IR (ATR): 1713, 1602, 1587, 1549, 1492, 1457, 1436, 1344, 1331 cm–1.
1H NMR (400 MHz):  = 8.12 (d, J =7.9 Hz, 1 H), 8.05 (d, J = 8.0 Hz, 1 H),
7.84 (t, J = 7.5 Hz, 1 H), 7.81–7.69 (m, 3 H), 7.06–6.97 (m, 2 H), 6.40–
6.33 (m, 1 H), 6.16 (s, 1 H), 5.81 (d, J = 7.0 Hz, 1 H), 5.17 (s, 1 H), 5.10
(t, J = 6.6 Hz, 1 H), 2.81–1.76 (m, 6 H).
13C NMR (126 MHz):  = 204.3 (C=O), 152.5, 142.8, 137.7, 132.2, 131.8,
130.9, 129.0, 128.9, 128.7, 126.5, 125.6, 122.7, 122.4, 121.6, 118.7,
117.3, 96.8, 95.1, 84.9, 76.4, 70.0, 52.9, 47.8, 29.7, 24.7.SynOpen 2021, 5, 1–16
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Obtained according to the general procedure from 1k (77 mg) and L-
proline.
Yield: 97 mg (71%); cream powder; mp 165–166 °C (decomp.).
IR (ATR): 1720, 1605, 1549, 1502, 1496, 1467, 1340, 1329 cm–1.
1H NMR (400 MHz):  = 8.18 (d, J = 7.8 Hz, 1 H), 8.05 (d, J = 8.2 Hz, 1
H), 7.84 (t, J = 7.5 Hz, 1 H), 7.81–7.69 (m, 3 H), 6.91 (d, J = 8.3 Hz, 1 H),
6.79 (br d, J = 8.3 Hz, 1 H), 6.07 (s, 1 H), 5.50 (s, 1 H), 5.17–5.06 (m, 2
H), 2.83–1.81 (m, 6 H), 1.58 (s, 1 H).
13C NMR (126 MHz):  = 204.5, 150.3, 142.8, 138.0, 132.03, 131.97,
130.9, 130.7, 129.4, 129.0, 128.8, 126.3, 126.0, 122.2, 121.6, 117.0,
116.2, 96.9, 95.0, 85.0, 76.3, 70.1, 53.4, 47.6, 29.6, 24.8, 20.4.





Obtained according to the general procedure from 1l (81 mg) and L-
proline.
Yield: 105 mg (75%); pale-yellow powder; mp 170–171 °C (decomp.).
IR (ATR): 1714, 1607, 1547, 1494, 1429, 1351, 1338 cm–1.
1H NMR (400 MHz):  = 8.18 (d, J = 8.0 Hz, 1 H), 8.06–8.01 (m, 1 H),
7.86–7.81 (m, 2 H), 7.78 (d, J = 6.9 Hz, 1 H), 7.74 (t, J = 7.5 Hz, 1 H),
6.94 (d, J = 8.9 Hz, 1 H), 6.79 (dd, J = 8.9, 2.6 Hz, 1 H), 5.96 (s, 1 H), 5.25
(d, J = 2.6 Hz, 1 H), 5.20 (s, 1 H), 5.09 (t, J = 6.8 Hz, 1 H), 2.86–1.80 (m,
9 H).
13C NMR (126 MHz):  = 204.4 (C=O), 154.8, 146.6, 142.8, 137.9, 132.1,
132.0, 130.9, 129.1, 128.9, 126.4, 122.4, 121.8, 119.4, 118.3, 115.8,
109.0, 96.8, 95.6, 85.6, 76.1, 70.2, 54.7, 53.9, 47.4, 29.4, 24.7.
Anal. Calcd for C27H21Cl3N2O5: C, 57.93; H, 3.78; N, 5.00. Found: C,




Obtained according to the general procedure from 1m (85 mg) and L-
proline.
Yield: 90 mg (62%); cream powder; mp 143–144 °C (decomp.).
IR (ATR): 1715, 1602, 1586, 1548, 1478, 1334 cm–1.
1H NMR (400 MHz):  = 8.17 (d, J = 7.8 Hz, 1 H), 8.05–7.99 (m, 1 H),
7.85–7.79 (m, 2 H), 7.75 (d, J = 6.8 Hz, 1 H), 7.72 (t, J = 7.5 Hz, 1 H),
6.61 (d, J = 8.0 Hz, 1 H), 6.28 (t, J = 7.9 Hz, 1 H), 6.06 (s, 1 H), 5.42 (d, J =
7.8 Hz, 1 H), 5.26 (s, 1 H), 5.09 (t, J = 6.9 Hz, 1 H), 4.09–3.98 (m, 2 H),
2.78–1.77 (m, 6 H), 1.39 (t, J = 6.9 Hz, 3 H).
13C NMR (126 MHz):  = 204.1 (C=O), 148.2, 142.9, 142.8, 137.9, 132.1,
132.0, 130.9, 129.0, 128.8, 126.3, 122.6, 122.2, 121.6, 120.0, 117.5,
114.1, 96.9, 95.6, 85.5, 76.0, 70.2, 65.6, 53.3, 47.3, 29.1, 24.7, 15.1.
Anal. Calcd for C28H23Cl3N2O5: С, 58.61; Н, 4.04; N, 4.88. Found: С,




Obtained according to the general procedure from 1n (82 mg) and L-
proline.
Yield: 116 mg (82%); white powder; mp 175–176 °C (decomp.).
IR (ATR): 1715, 1600, 1551, 1481, 1467, 1435, 1339 cm–1.
1H NMR (400 MHz):  = 8.21 (d, J = 7.9 Hz, 1 H), 8.07 (d, J = 7.9 Hz, 1
H), 7.85 (t, J = 7.5 Hz, 1 H), 7.81–7.73 (m, 3 H), 7.01–6.94 (m, 2 H), 6.16
(s, 1 H), 5.71 (s, 1 H), 5.10 (t, J = 6.6 Hz, 1 H), 5.06 (s, 1 H), 2.78–1.80
(m, 6 H).
13C NMR (126 MHz):  = 204.2 (C=O), 150.9, 142.8, 137.2, 132.4, 131.6,
130.9, 129.1, 129.0, 128.9, 127.6, 126.7, 125.5, 122.6, 121.6, 120.3,
118.7, 96.6, 94.2, 84.7, 76.3, 70.0, 52.8, 47.8, 29.7, 24.8.
Anal. Calcd for C26H18Cl4N2O4: С, 55.35; Н, 3.22; N, 4.96. Found: С,




Obtained according to the general procedure from 1o (91 mg) and L-
proline.
Yield: 117 mg (82%); cream powder; mp 165–166 °C (decomp.).
IR (ATR): 1722, 1599, 1546, 1464, 1339 cm–1.
1H NMR (400 MHz):  = 8.22 (d, J = 7.8 Hz, 1 H), 8.08 (d, J = 8.3 Hz, 1
H), 7.85 (dd, J = 8.3, 7.2 Hz, 1 H), 7.82–6.74 (m, 3 H), 7.10 (d, J = 2.3 Hz,
1 H), 6.20 (s, 1 H), 5.63 (d, J = 2.3 Hz, 1 H), 5.08 (dd, J = 7.8, 6.7 Hz, 1 H),
5.07 (s, 1 H), 2.75–1.81 (m, 6 H).
13C NMR (126 MHz):  = 204.0 (C=O), 147.1, 142.8, 136.9, 132.6, 131.5,
130.9, 129.3, 129.1, 129.0, 127.3, 126.9, 123.9, 123.7, 122.8, 121.6,
121.5, 96.1, 94.1, 85.0, 76.2, 69.9, 52.9, 47.7, 29.7, 24.7.
Anal. Calcd for C26H17Cl5N2O4: С, 52.16; Н, 2.86; N, 4.68. Found: С,




Obtained according to the general procedure from 1p (85 mg) and L-
proline.
Yield: 114 mg (79%); beige powder; mp 163–164 °C (decomp.).
IR (ATR): 1720, 1591, 1546, 1524, 1492, 1343, 1329 cm–1.
1H NMR (400 MHz):  = 8.25–8.20 (m, 1 H), 8.12 (d, J = 8.4 Hz, 1 H),
7.95–7.87 (m, 2 H), 7.76 (d, J = 7.0 Hz, 1 H), 7.74–7.71 (m, 2 H), 7.15
(d, J = 9.0 Hz, 1 H), 6.66 (d, J = 2.2 Hz, 1 H), 6.41 (s, 1 H), 5.15 (dd, J =
8.0, 6.8 Hz, 1 H), 4.99 (s, 1 H), 2.79–1.82 (m, 6 H).
13C NMR (126 MHz):  = 204.4 (C=O), 156.9, 142.9, 142.3, 136.5, 132.9,
131.1, 131.0, 129.2, 129.1, 127.2, 124.7, 122.8, 122.1, 121.6, 119.0,
117.9, 96.0, 92.5, 84.3, 76.7, 70.0, 52.4, 48.2, 30.2, 24.8.





Obtained according to the general procedure from 1q (96 mg) and L-
proline.SynOpen 2021, 5, 1–16
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IR (ATR): 1713, 1606, 1553, 1544, 1474, 1345 cm–1.
1H NMR (400 MHz):  = 8.56 (d, J = 2.7 Hz, 1 H), 8.26 (dd, J = 7.3, 1.6
Hz, 1 H), 8.15 (d, J = 8.3 Hz, 1 H), 7.78–7.74 (m, 3 H), 6.87 (dd, J = 2.7,
0.6 Hz, 1 H), 6.62 (s, 1 H), 5.16 (dd, J = 8.8, 6.1 Hz, 1 H), 4.97 (s, 1 H),
2.79–1.85 (m, 6 H).
13C NMR (126 MHz):  = 203.9 (C=O), 150.2, 142.9, 140.5, 138.0, 135.8,
133.2, 131.1, 130.7, 129.4, 129.2, 127.5, 125.1, 123.3, 122.6, 121.6,
121.1, 95.0, 91.0, 84.7, 76.9, 69.9, 51.8, 48.3, 30.3, 24.8.
Anal. Calcd for C26H17Cl3N4O8: C, 50.39; H, 2.76; N, 9.04. Found: C,




Obtained according to the general procedure from 1a (61 mg) and L-
thiaproline.
Yield: 70 mg (56%); cream powder; mp 248–249 °C (decomp.).
IR (ATR): 1728, 1603, 1590, 1549, 1492, 1459, 1447, 1404, 1366, 1337
cm–1.
1H NMR (400 MHz):  = 8.20 (dd, J = 7.2, 1.5 Hz, 1 H), 8.07 (d, J = 8.1
Hz, 1 H), 7.89 (d, J = 7.2 Hz, 1 H), 7.84 (t, J = 6.8 Hz, 1 H), 7.75–7.67 (m,
2 H), 6.96–7.08 (m, 2 H), 6.44 (q, J = 5.7 Hz, 1 H), 6.36 (t, J = 7.8 Hz, 1
H), 5.64 (d, J = 7.8 Hz, 1 H), 4.68 (s, 1 H), 4.65 (dd, J = 10.3, 5.8 Hz, 1 H),
4.14 (d, J = 9.9 Hz, 1 H), 3.64 (dd, J = 10.3, 5.8 Hz, 1 H), 3.34 (d, J = 9.9
Hz, 1 H), 2.83 (t, J = 10.3 Hz, 1 H).
19F NMR (376 MHz):  = 90.7 (d, J = 5.7 Hz, CF3).
13C NMR (126 MHz):  = 203.3 (C=O), 151.3, 143.1, 135.0, 132.5,
130.62, 130.60, 129.4, 129.3, 128.9, 127.0, 126.3, 122.8, 122.7 (q, J =
282.1 Hz, CF3), 122.6, 122.4, 117.3, 116.6, 88.6, 77.5, 74.2 (q, J = 32.6
Hz, C-6′), 70.7 (q, J = 3.8 Hz, C-6b′), 54.9, 49.6, 36.8.





Obtained according to the general procedure from 1c (69 mg) and L-
thiaproline.
Yield: 80 mg (92%); cream powder; mp 224–225 °C (decomp.).
IR (ATR): 1723, 1617, 1603, 1555, 1496, 1467, 1442, 1427, 1365, 1334
cm–1.
1H NMR (400 MHz):  = 8.24–8.17 (m, 1 H), 8.06 (d, J = 7.9 Hz, 1 H),
7.92–7.83 (m, 2 H), 7.77–7.70 (m, 2 H), 6.91 (d, J = 9.0 Hz, 1 H), 6.60
(dd, J = 9.0, 2.3 Hz, 1 H), 6.32 (q, J = 5.5 Hz, 1 H), 5.05 (d, J = 2.3 Hz, 1
H), 4.66 (dd, J = 10.4, 5.8 Hz, 1 H), 4.64 (s, 1 H), 4.15 (d, J = 9.8 Hz, 1 H),
3.63 (dd, J = 10.4, 5.8 Hz, 1 H), 3.39 (d, J = 9.8 Hz, 1 H), 2.86 (s, 3 H),
2.81 (t, J = 10.4 Hz, 1 H).
19F NMR (376 MHz):  = 90.8 (d, J = 5.5 Hz, CF3).
13C NMR (126 MHz):  = 203.2 (C=O), 154.5, 145.4, 142.9, 135.2, 132.4,
130.9, 130.6, 129.4, 128.9, 126.9, 122.8 (2C), 122.7 (q, J = 281.8 Hz,
CF3), 118.3, 117.1, 116.4, 109.9, 88.9, 77.6, 74.4 (q, J = 32.8 Hz, C-6′),
70.6 (q, J = 3.8 Hz, C-6b′), 54.9, 54.8, 50.3, 36.8.





Obtained according to the general procedure from 1f (79 mg) and L-
thiaproline.
Yield: 102 mg (72%); grey powder; mp 229–230 °C (decomp.).
IR (ATR): 1721, 1600, 1557, 1467, 1390, 1364, 1345, 1329 cm–1.
1H NMR (400 MHz):  = 8.27–8.21 (m, 1 H), 8.10 (d, J = 8.3 Hz, 1 H),
7.89 (t, J = 7.7 Hz, 1 H), 7.82 (d, J = 7.0 Hz, 1 H), 7.80–7.74 (m, 2 H),
7.14 (d, J = 2.2 Hz, 1 H), 6.45 (q, J = 5.5 Hz, 1 H), 5.49 (d, J = 2.2 Hz, 1 H),
4.64 (dd, J = 10.4, 5.8 Hz, 1 H), 4.59 (s, 1 H), 4.15 (d, J = 9.9 Hz, 1 H),
3.65 (dd, J = 10.4, 5.8 Hz, 1 H), 3.34 (d, J = 9.9 Hz, 1 H), 2.79 (t, J = 10.4
Hz, 1 H).
19F NMR (376 MHz):  = 90.7 (d, J = 5.5 Hz, CF3).
13C NMR (126 MHz):  = 202.9 (C=O), 146.2, 143.0, 134.2, 133.0, 130.6,
130.2, 130.0, 129.3, 129.1, 127.4, 127.2, 124.5, 123.6, 123.2, 122.7,
122.3 (q, J = 282.0 Hz, CF3), 119.7, 88.1, 77.3, 74.7 (q, J = 33.3 Hz, C-6′),
70.4 (q, J = 3.6 Hz, C-6b′), 54.8, 49.5, 36.8.





Obtained according to the general procedure from 1h (73 mg) and L-
thiaproline.
Yield: 90 mg (66%); beige powder; mp 244–245 °C (decomp.).
IR (ATR): 1718, 1590, 1557, 1519, 1488, 1362, 1340, 1330 cm–1.
1H NMR (400 MHz):  = 8.25 (d, J = 7.9 Hz, 1 H, Ar), 8.14 (d, J = 7.9 Hz,
1 H), 7.97 (dd, J = 9.0, 2.0 Hz, 1 H), 7.96–7.84 (m, 2 H), 7.75–7.65 (m, 2
H), 7.13 (d, J = 9.0 Hz, 1 H), 6.56 (q, J = 5.6 Hz, 1 H), 6.54 (d, J = 2.0 Hz,
1 H), 4.70–4.59 (m, 2 H), 4.18 (d, J = 10.0 Hz, 1 H), 3.70 (dd, J = 10.4,
5.7 Hz, 1 H), 3.40 (d, J = 10.0 Hz, 1 H), 2.84 (t, J = 10.4 Hz, 1 H).
19F NMR (376 MHz):  = 90.4 (d, J = 5.6 Hz, CF3).
13C{1H} NMR (126 MHz):  = 203.2 (C=O), 155.9, 143.1, 142.3, 133.9,
133.3, 130.8, 130.0, 129.5, 129.1, 127.6, 125.3, 123.4, 122.8, 122.6,
122.3 (q, J = 282.0 Hz, CF3), 118.1, 117.7, 87.5, 77.5, 74.8 (q, J = 33.3 Hz,
C-6′), 70.6 (q, J = 3.8 Hz, C-6b′), 54.8, 49.4, 36.8.





Obtained according to the general procedure from 1j (74 mg) and L-
thiaproline.
Yield: 53 mg (39%); beige powder; mp 204–205 °C (decomp.).
IR (ATR): 1723, 1596, 1547, 1493, 1456, 1436, 1364, 1345, 1327 cm–1.
1H NMR (400 MHz):  = 8.22–8.16 (m, 1 H), 8.07 (d, J = 7.8 Hz, 1 H),
7.92–7.81 (m, 2 H), 7.74–7.64 (m, 2 H), 7.09–6.97 (m, 2 H), 6.67 (s, 1
H), 6.33 (t, J = 7.3 Hz, 1 H), 5.62 (d, J = 7.3 Hz, 1 H), 5.48 (dd, J = 10.4,
5.7 Hz, 1 H), 4.66 (s, 1 H), 4.17 (d, J = 9.9 Hz, 1 H), 3.72 (dd, J = 10.4, 5.7
Hz, 1 H), 3.36 (d, J = 9.9 Hz, 1 H), 2.84 (t, J = 10.4 Hz, 1 H).
13C{1H} NMR (126 MHz):  = 203.4 (C=O), 151.8, 143.2, 134.9, 132.5,
130.63, 130.57, 129.4, 129.2, 128.9, 126.9, 125.8, 122.8, 122.7, 122.1,
116.9, 116.4, 96.5, 90.2, 81.8, 77.5, 71.8, 55.1, 51.0, 37.4.SynOpen 2021, 5, 1–16
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Obtained according to the general procedure from 1l (81 mg) and L-
thiaproline.
Yield: 52 mg (36%); brown powder; mp 192–193 °C (decomp.).
IR (ATR): 1716, 1602, 1545, 1502, 1462, 1434, 1344 cm–1.
1H NMR (400 MHz):  = 8.24–8.15 (m, 1 H), 8.06 (d, J = 7.5 Hz, 1 H),
7.92–7.83 (m, 2 H), 7.76–7.68 (m, 2 H), 6.95 (d, J = 8.9 Hz, 1 H), 6.60
(dd, J = 8.9, 2.2 Hz, 1 H), 6.55 (s, 1 H), 5.49 (dd, J = 10.4, 5.8 Hz, 1 H),
5.04 (d, J = 2.2 Hz, 1 H), 4.62 (s, 1 H), 4.18 (d, J = 9.8 Hz, 1 H), 3.72 (dd,
J = 10.4, 5.7 Hz, 1 H), 3.41 (d, J = 9.8 Hz, 1 H), 2.85 (s, 3 H), 2.83 (t, J =
10.4 Hz, 1 H).
13C NMR (126 MHz):  = 203.3 (C=O), 154.3, 145.9, 143.1, 135.1, 132.3,
130.9, 130.5, 129.4, 128.9, 126.9, 122.9, 122.7, 118.0, 116.9, 116.4,
109.4, 96.5, 90.5, 82.0, 77.5, 71.7, 55.0, 54.9, 51.7, 37.4.





Obtained according to the general procedure from 1o (91 mg) and L-
thiaproline.
Yield: 95 mg (65%); beige powder; mp 224–255 °C (decomp.).
IR (ATR): 1716, 1599, 1553, 1453, 1432, 1364, 1327 cm–1.
1H NMR (400 MHz):  = 8.27–8.20 (m, 1 H), 8.10 (d, J = 8.1 Hz, 1 H),
7.94–7.70 (m, 4 H), 7.13 (d, J = 2.2 Hz, 1 H), 6.67 (s, 1 H), 5.52–5.40 (m,
2 H), 4.58 (s, 1 H), 4.17 (d, J = 9.9 Hz, 1 H), 3.72 (dd, J = 10.3, 5.8 Hz, 1
H), 3.36 (d, J = 9.9 Hz, 1 H), 2.81 (t, J = 10.3 Hz, 1 H).
13C NMR (126 MHz):  = 203.0 (C=O), 146.7, 143.1, 134.1, 132.9, 130.6,
130.3, 129.8, 129.3, 129.1, 127.4, 126.8, 124.0, 123.3, 123.2, 122.8,
119.3, 95.9, 89.7, 82.2, 77.3, 71.6, 55.0, 50.9, 37.4.





Obtained according to the general procedure from 1q (96 mg) and L-
thiaproline.
Yield: 110 mg (69%); beige powder; mp 214–215 °C (decomp.).
IR (ATR): 1708, 1602, 1557, 1547, 1535, 1479, 1340 cm–1.
1H NMR (400 MHz):  = 8.62 (d, J = 1.8 Hz, 1 H), 8.30–8.24 (m, 1 H),
8.17 (d, J = 8.0 Hz, 1 H), 7.95 (t, J = 7.6 Hz, 1 H), 7.91 (d, J = 6.9 Hz, 1 H),
7.78–7.70 (m, 2 H), 6.93 (s, 1 H), 6.75 (d, J = 1.8 Hz, 1 H), 5.47 (dd, J =
10.4, 5.8 Hz, 1 H), 4.69 (s, 1 H), 4.21 (d, J = 10.2 Hz, 1 H), 3.79 (dd, J =
10.4, 5.8 Hz, 1 H), 3.39 (d, J = 10.2 Hz, 1 H), 2.85 (t, J = 10.4 Hz, 1 H).
13C NMR (126 MHz):  = 202.9 (C=O), 149.9, 143.3, 140.2, 137.6, 133.6,
133.0, 130.7, 129.6, 129.5, 129.3, 128.0, 125.2, 123.7, 123.1, 121.7,
121.1, 94.7, 88.0, 83.2, 77.3, 71.8, 54.9, 50.2, 37.2.
HRMS (ESI): m/z [M + H]+ calcd for C25H17Cl3N3O6S: 636.9749; found:
636.9744.
Synthesis of Spirochromeno[3,4-a]indolizidines 6 and 7; General 
Procedure
A suspension of the requisite nitrochromene 1 (0.25 mmol), acenaph-
thenequinone (46 mg, 0.25 mmol) and L-pipecolic acid (43 mg, 0.33
mmol) or (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (58
mg, 0.33 mmol) in DMSO (2 mL, 100 L of H2O was added to the reac-
tion mixture in order to dissolve the pipecolic acid) was stirred at 60
°C for 7 h (compounds 6) or at 70 °C for 12 h (compounds 7). Then the
mixture was cooled to r.t., water (4 mL) was added, the precipitate
was filtered off, washed with H2O (5 × 1 mL) and dried at 60 °C. After
drying, compounds 7 were purified by column chromatography on




Obtained according to the general procedure from 1a (61 mg) and L-
pipecolic acid.
Yield: 72 mg (58%); pale-yellow powder; mp 231–232 °C (decomp.).
IR (ATR): 1703, 1605, 1585, 1562, 1487, 1457, 1409, 1354, 1342, 1338
cm–1.
1H NMR (500 MHz):  = 8.18 (d, J = 8.0 Hz, 1 H), 8.03 (d, J = 8.2 Hz, 1
H), 7.98 (d, J = 6.9 Hz, 1 H), 7.87 (t, J = 7.6 Hz, 1 H), 7.71 (t, J = 7.5 Hz, 1
H), 7.66 (d, J = 6.9 Hz, 1 H), 7.04–6.90 (m, 1 H), 6.36 (t, J = 7.6 Hz, 1 H),
5.80 (d, J = 7.6 Hz, 1 H), 5.55 (q, J = 6.3 Hz, 1 H), 5.23 (s, 1 H), 4.02 (d,
J = 10.2 Hz, 1 H), 2.43–1.10 (m, 8 H).
19F NMR (471 MHz):  = 95.0 (br s, CF3).
13C NMR (126 MHz):  = 207.6 (C=O), 153.0, 143.2, 138.6, 132.4, 132.3,
130.6, 129.6, 128.8, 128.7, 126.6, 126.1, 123.3 (q, J = 282.1 Hz, CF3),
123.2, 121.3, 121.1, 118.7, 117.7, 96.1, 78.4, 77.4 (q, J = 33.8 Hz, C-6′),
65.0, 50.8, 46.3, 28.9, 25.1, 24.3.





Obtained according to the general procedure from 1b (65 mg) and L-
pipecolic acid.
Yield: 79 mg (62%); yellow powder; mp 221–222 °C (decomp.).
IR (ATR): 1706, 1606, 1557, 1502, 1464, 1439, 1403, 1336 cm–1.
1H NMR (400 MHz):  = 8.18 (d, J = 8.0 Hz, 1 H), 8.03 (d, J = 8.3 Hz, 1
H), 7.98 (d, J = 6.9 Hz, 1 H), 7.87 (dd, J = 8.3, 6.9 Hz, 1 H), 7.70 (t, J = 7.5
Hz, 1 H), 7.65 (d, J = 6.9 Hz, 1 H), 6.84 (d, J = 8.4 Hz, 1 H), 6.77 (dd, J =
8.4, 1.4 Hz, 1 H), 5.49 (d, J = 1.4 Hz, 1 H), 5.46 (q, J = 6.8 Hz, 1 H), 5.14
(s, 1 H), 4.05 (d, J = 10.5 Hz, 1 H), 2.42–1.11 (m, 11 H).
19F NMR (376 MHz):  = 95.3 (br s, CF3).
13C NMR (126 MHz):  = 207.5 (C=O), 150.7, 143.2, 138.9, 132.5, 132.4,
132.2, 130.6, 129.7, 129.5, 128.6, 127.1, 125.9, 123.4 (q, J = 283.0 Hz,
CF3), 121.3, 120.9, 118.5, 117.3, 96.1, 78.5, 65.1, 51.0, 46.4, 28.9, 25.2,
24.2, 20.3 (the signal of the C-6′ atom overlaps with the signal of CD-
Cl3).
HRMS (ESI): m/z [M + H]+ calcd for C28H24F3N2O4: 509.1683; found:
509.1682.SynOpen 2021, 5, 1–16
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methyl)-6a′,6b′,7′,9′,10′,12a′-hexahydro-2H,6′H,8′H-spiro[ace-
naphthylene-1,12′-chromeno[3,4-a]indolizin]-2-one (6c)
Obtained according to the general procedure from 1c (69 mg) and L-
pipecolic acid.
Yield: 76 mg (58%); pale-yellow powder; mp 210–211 °C (decomp.).
IR (ATR): 1705, 1604, 1566, 1499, 1466, 1423, 1409, 1357, 1335 cm–1.
1H NMR (400 MHz):  = 8.18 (d, J = 8.0 Hz, 1 H), 8.05–7.95 (m, 2 H),
7.87 (t, J = 7.6 Hz, 1 H), 7.76–7.65 (m, 2 H), 6.86 (d, J = 8.9 Hz, 1 H),
6.52 (dd, J = 8.9, 2.0 Hz, 1 H), 5.43 (q, J = 6.6 Hz, 1 H), 5.20 (d, J = 2.0 Hz,
1 H), 5.18 (s, 1 H), 4.04 (d, J = 10.3 Hz, 1 H), 2.73 (s, 3 H), 2.46–1.11 (m,
8 H).
19F NMR (376 MHz):  = 94.9 (br s, CF3).
13C{1H} NMR (126 MHz):  = 207.5 (C=O), 154.9, 146.9, 143.2, 138.8,
132.5, 132.2, 130.6, 129.7, 128.7, 126.0, 123.3 (q, J = 282.4 Hz, CF3),
121.4, 121.2, 119.0, 118.6, 116.3, 109.5, 96.0, 78.4, 77.7 (q, J = 33.3 Hz,
C-6′), 65.1, 54.6, 51.4, 46.4, 28.9, 25.1, 24.3.





Obtained according to the general procedure from 1d (72 mg) and L-
pipecolic acid.
Yield: 75 mg (56%); pale-yellow powder; mp 235–236 °C (decomp.).
IR (ATR): 1703, 1607, 1586, 1557, 1487, 1475, 1452, 1444, 1438, 1377,
1345, 1334 cm–1.
1H NMR (400 MHz):  = 8.16 (d, J = 8.0 Hz, 1 H), 8.01 (d, J = 7.0 Hz, 1
H), 8.00 (d, J = 8.3 Hz, 1 H), 7.85 (dd, J = 8.3, 7.0 Hz, 1 H), 7.69 (dd, J =
8.0, 7.0 Hz, 1 H), 7.63 (d, J = 7.0 Hz, 1 H), 6.59 (d, J = 8.0 Hz, 1 H), 6.29
(t, J = 8.0 Hz, 1 H), 5.52 (q, J = 6.8 Hz, 1 H), 5.41 (d, J = 8.0 Hz, 1 H), 5.19
(s, 1 H), 4.11 (dd, J = 10.7, 1.5 Hz, 1 H), 4.04 (dq, J = 9.5, 7.0 Hz, 1 H),
4.00 (dq, J = 9.5, 7.0 Hz, 1 H), 2.34–1.07 (m, 11 H).
19F NMR (376 MHz):  = 95.9 (br s, CF3).
13C NMR (126 MHz):  = 206.9 (C=O), 148.4, 143.1, 142.9, 139.0, 132.4,
132.1, 130.6, 129.6, 128.6, 125.9, 123.4 (q, J = 284.0 Hz, CF3), 123.0,
121.5, 120.9, 120.6, 118.2, 113.2, 96.2, 78.5, 77.1 (q, J = 32.2 Hz, C-6′),
65.1, 65.0, 50.7, 46.3, 28.8, 25.1, 24.1, 14.9.





Obtained according to the general procedure from 1e (70 mg) and L-
pipecolic acid.
Yield: 87 mg (62%); beige powder; mp 214–215 °C (decomp.).
IR (ATR): 1705, 1605, 1557, 1481, 1402, 1336 cm–1.
1H NMR (400 MHz):  = 8.21 (d, J = 7.7 Hz, 1 H), 8.06 (d, J = 8.2 Hz, 1
H), 8.01–7.64 (m, 4 H), 6.99–6.85 (m, 2 H), 5.69 (s, 1 H), 5.52 (q, J = 6.4
Hz, 1 H), 5.14 (s, 1 H), 4.03 (d, J = 10.2 Hz, 1 H), 2.43–1.10 (m, 8 H).
19F NMR (376 MHz):  = 95.1 (br s, CF3).
13C NMR (126 MHz):  = 207.4 (C=O), 151.4, 143.2, 138.0, 132.6, 132.1,
130.7, 129.7, 129.0, 128.8, 128.2, 126.6, 126.3, 123.1 (q, J = 282.7 Hz,
CF3), 121.34, 121.31, 120.5, 119.0, 95.5, 78.3, 77.3 (q, J = 34.0 Hz, C-6′),
65.1, 50.6, 46.4, 28.9, 25.1, 24.2.





Obtained according to the general procedure from 1f (79 mg) and L-
pipecolic acid.
Yield: 85 mg (60%); yellow powder; mp 219–220 °C (decomp.).
IR (ATR): 1699, 1605, 1557, 1481, 1441, 1402, 1336 cm–1.
1H NMR (400 MHz):  = 8.21 (d, J = 8.0 Hz, 1 H), 8.05 (d, J = 8.3 Hz, 1
H), 8.00 (d, J = 6.9 Hz, 1 H), 7.88 (dd, J = 8.3, 6.9 Hz, 1 H), 7.74 (t, J = 7.5
Hz, 1 H), 7.70 (d, J = 6.9 Hz, 1 H), 7.09 (d, J = 1.8 Hz, 1 H), 5.64 (d, J = 1.8
Hz, 1 H), 5.56 (q, J = 6.7 Hz, 1 H), 5.13 (s, 1 H), 4.08 (d, J = 10.2 Hz, 1 H),
2.40–1.11 (m, 8 H).
19F NMR (376 MHz):  = 95.5 (br s, CF3).
13C NMR (126 MHz):  = 207.7 (C=O), 147.4, 143.1, 137.8, 132.7, 132.0,
130.6, 129.7, 129.4, 128.9, 128.1, 126.4, 125.0, 124.2, 122.9 (q, J =
283.6 Hz, CF3), 122.3, 121.5, 121.4, 95.4, 78.3, 65.0, 50.5, 46.3, 28.8,
25.0, 24.0 (the signal of the C-6′ atom overlaps with the signal of
CDCl3).





Obtained according to the general procedure from 1g (92 mg) and L-
pipecolic acid.
Yield: 92 mg (60%); yellow powder; mp 211–212 °C (decomp.).
IR (ATR): 1700, 1602, 1554, 1487, 1473, 1422, 1401, 1344, 1329 cm–1.
1H NMR (400 MHz):  = 8.19 (d, J = 8.0 Hz, 1 H), 8.03 (d, J = 8.4 Hz, 1
H), 8.01 (d, J = 7.0 Hz, 1 H), 7.86 (dd, J = 8.4, 7.0 Hz, 1 H), 7.72 (dd, J =
8.0, 7.0 Hz, 1 H), 7.67 (d, J = 7.0 Hz, 1 H), 6.70 (d, J = 2.0 Hz, 1 H), 5.48
(q, J = 6.8 Hz, 1 H), 5.46 (d, J = 2.0 Hz, 1 H), 5.07 (s, 1 H), 4.13 (d, J =
10.5 Hz, 1 H), 4.01 (dq, J = 9.3, 6.9 Hz, 1 H), 3.99 (dq, J = 9.3, 6.9 Hz, 1
H), 2.38–1.07 (m, 11 H).
19F NMR (376 MHz):  = 96.1 (br s, CF3).
13C NMR (126 MHz):  = 206.7 (C=O), 149.1, 143.0, 141.6, 138.4, 132.3,
132.2, 130.6, 129.6, 128.7, 126.1, 123.2 (q, J = 284.4 Hz, CF3), 122.3,
121.5, 121.1, 120.9, 116.1, 115.4, 95.7, 78.4, 65.3, 65.1, 50.3, 46.3,
28.7, 25.1, 23.9, 14.7 (the signal of the C-6′ atom overlaps with the
signal of CDCl3).





Obtained according to the general procedure from 1h (73 mg) and L-
pipecolic acid.
Yield: 90 mg (67%); yellow powder; mp 241–242 °C (decomp.).
IR (ATR): 1697, 1603, 1585, 1565, 1527, 1483, 1434, 1341 cm–1.SynOpen 2021, 5, 1–16
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H), 8.00 (d, J = 6.9 Hz, 1 H), 7.92 (dd, J = 8.3, 6.9 Hz, 1 H), 7.87 (dd, J =
9.0, 2.2 Hz, 1 H), 7.71 (t, J = 7.5 Hz, 1 H), 7.66 (d, J = 6.9 Hz, 1 H), 7.09
(d, J = 9.0 Hz, 1 H), 6.64 (d, J = 2.2 Hz, 1 H), 5.66 (q, J = 6.4 Hz, 1 H), 5.19
(s, 1 H), 4.05 (d, J = 10.7 Hz, 1 H), 2.51–1.18 (m, 8 H).
19F NMR (376 MHz):  = 94.7 (br s, CF3).
13C NMR (126 MHz):  = 207.7 (C=O), 157.4, 143.3, 143.0, 137.2, 133.2,
131.9, 130.9, 129.8, 128.9, 126.8, 124.6, 123.0, 122.8 (q, J = 282.3 Hz,
CF3), 121.5, 121.4, 119.5, 118.6, 94.8, 78.4, 77.6 (q, J = 34.5 Hz, C-6′),
65.3, 50.7, 46.4, 29.0, 25.0, 24.3.





Obtained according to the general procedure from 1j (74 mg) and L-
pipecolic acid.
Yield: 58 mg (43%); yellow powder; mp 219–220 °C (decomp.).
IR (ATR): 1701, 1606, 1554, 1489, 1455, 1443, 1329 cm–1.
1H NMR (500 MHz):  = 8.17 (d, J = 8.0 Hz, 1 H), 8.02 (d, J = 8.2 Hz, 1
H), 7.93 (d, J = 6.9 Hz, 1 H), 7.86 (t, J = 7.6 Hz, 1 H), 7.69 (t, J = 7.5 Hz, 1
H), 7.65 (d, J = 6.9 Hz, 1 H), 7.02–6.98 (m, 2 H), 6.38–6.34 (m, 1 H),
5.81 (d, J = 8.0 Hz, 1 H), 5.80 (s, 1 H), 5.18 (s, 1 H), 4.44 (d, J = 9.4 Hz, 1
H), 2.66–1.22 (m, 8 H).
13C NMR (126 MHz):  = 207.7 (C=O), 152.4, 143.3, 138.8, 132.34,
132.29, 130.6, 129.6, 128.7 (2C), 126.2, 126.0, 123.1, 121.3, 121.1,
119.5, 117.8, 97.6, 97.5, 85.8, 78.2, 66.0, 51.7, 46.8, 30.5, 25.2, 24.6.





Obtained according to the general procedure from 1k (77 mg) and L-
pipecolic acid.
Yield: 62 mg (44%); yellow powder; mp 223–224 °C (decomp.).
IR (ATR): 1698, 1605, 1550, 1498, 1443, 1432, 1339, 1331 cm–1.
1H NMR (400 MHz):  = 8.16 (d, J = 8.0 Hz, 1 H), 8.02 (d, J = 8.3 Hz, 1
H), 7.95 (d, J = 6.8 Hz, 1 H), 7.86 (t, J = 7.6 Hz, 1 H), 7.69 (t, J = 7.5 Hz, 1
H), 7.63 (d, J = 6.9 Hz, 1 H), 6.88 (d, J = 8.2 Hz, 1 H), 6.79 (dd, J = 8.2, 1.5
Hz, 1 H), 5.70 (s, 1 H), 5.51 (d, J = 1.5 Hz, 1 H), 5.11 (s, 1 H), 4.46 (d, J =
9.6 Hz, 1 H), 2.60–1.23 (m, 8 H).
13C NMR (126 MHz):  = 207.5 (C=O), 149.9, 143.2, 139.1, 132.5, 132.3,
132.0, 130.5, 129.6, 129.3, 128.5, 126.8, 125.8, 121.4, 120.8, 119.5,
117.6, 97.73, 97.65, 85.8, 78.3, 66.1, 51.7, 46.8, 30.3, 25.2, 24.5, 20.4.





Obtained according to the general procedure from 1l (81 mg) and L-
pipecolic acid.
Yield: 75 mg (52%); yellow powder; mp 229–230 °C (decomp.).
IR (ATR): 1698, 1605, 1552, 1493, 1468, 1454, 1447, 1429, 1377, 1341
cm–1.
1H NMR (400 MHz):  = 8.16 (d, J = 7.4 Hz, 1 H), 8.00 (d, J = 8.2 Hz, 1
H), 7.95 (d, J = 6.8 Hz, 1 H), 7.86 (t, J = 7.6 Hz, 1 H), 7.74–7.65 (m, 2 H),
6.91 (d, J = 8.9 Hz, 1 H), 6.54 (dd, J = 8.9, 2.1 Hz, 1 H), 5.67 (s, 1 H), 5.25
(d, J = 2.1 Hz, 1 H), 5.14 (s, 1 H), 4.46 (d, J = 8.7 Hz, 1 H), 2.75 (s, 3 H),
2.65–1.21 (m, 8 H).
13C NMR (126 MHz):  = 207.5 (C=O), 154.9, 146.3, 143.2, 139.0, 132.6,
132.1, 130.6, 129.7, 128.7, 125.9, 121.4, 121.1, 119.9, 118.8, 116.2,
109.3, 97.6, 97.5, 86.2, 78.2, 66.0, 54.6, 52.1, 46.9, 30.5, 25.2, 24.6.





Obtained according to the general procedure from 1m (85 mg) and L-
pipecolic acid.
Yield: 87 mg (59%); yellow powder; mp 222–223 °C (decomp.).
IR (ATR): 1708, 1607, 1586, 1548, 1488, 1470, 1435, 1392, 1335 cm–1.
1H NMR (400 MHz):  = 8.14 (d, J = 7.6 Hz, 1 H), 8.05–7.94 (m, 2 H),
7.84 (t, J = 7.5 Hz, 1 H), 7.67 (t, J = 7.4 Hz, 1 H), 7.60 (d, J = 6.7 Hz, 1 H),
6.61 (d, J = 8.0 Hz, 1 H), 6.32 (t, J = 8.0 Hz, 1 H), 5.77 (s, 1 H), 5.45 (d, J =
8.0 Hz, 1 H), 5.22 (s, 1 H), 4.48 (d, J = 9.1 Hz, 1 H), 4.17–3.93 (m, 2 H),
2.53–1.14 (m, 11 H).
13C NMR (126 MHz):  = 206.6 (C=O), 148.5, 143.0, 141.4, 139.3, 132.5,
131.9, 130.5, 129.6, 128.5, 125.7, 123.2, 122.0, 121.6, 120.7, 118.1,
113.2, 98.2, 97.9, 85.9, 78.3, 66.2, 65.1, 51.2, 46.6, 29.8, 25.2, 24.1,
15.1.





Obtained according to the general procedure from 1n (82 mg) and L-
pipecolic acid.
Yield: 87 mg (60%); yellow powder; mp 222–223 °C (decomp.).
IR (ATR): 1698, 1605, 1554, 1482, 1446, 1432, 1339 cm–1.
1H NMR (400 MHz):  = 8.20 (d, J = 8.0 Hz, 1 H), 8.05 (d, J = 8.3 Hz, 1
H), 7.93 (d, J = 6.8 Hz, 1 H), 7.87 (t, J = 7.6 Hz, 1 H), 7.73 (t, J = 7.5 Hz, 1
H), 7.69 (d, J = 6.9 Hz, 1 H), 6.97 (dd, J = 8.8, 1.8 Hz, 1 H), 6.94 (d, J = 8.8
Hz, 1 H), 5.76 (s, 1 H), 5.71 (br s, 1 H), 5.09 (s, 1 H), 4.44 (d, J = 9.4 Hz,
1 H), 2.66–1.21 (m, 8 H).
13C NMR (126 MHz):  = 207.5 (C=O), 150.7, 143.2, 138.3, 132.5, 132.2,
130.6, 129.6, 128.83, 128.78, 128.1, 126.26, 126.24, 121.4, 121.3,
121.3, 111.3, 97.3, 97.0, 85.7, 78.2, 66.1, 51.4, 46.8, 30.4, 25.1, 24.6.





Obtained according to the general procedure from 1o (91 mg) and L-
pipecolic acid.
Yield: 100 mg (65%); pale-yellow powder; mp 199–200 °C (decomp.).
IR (ATR): 1704, 1603, 1555, 1493, 1464, 1442, 1433, 1420, 1409, 1329
cm–1.SynOpen 2021, 5, 1–16
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H), 7.95 (d, J = 6.8 Hz, 1 H), 7.87 (t, J = 7.6 Hz, 1 H), 7.73 (t, J = 7.5 Hz, 1
H), 7.69 (d, J = 6.9 Hz, 1 H), 7.09 (d, J = 1.8 Hz, 1 H), 5.82 (s, 1 H), 5.65
(d, J = 1.8 Hz, 1 H), 5.10 (s, 1 H), 4.42 (d, J = 9.5 Hz, 1 H), 2.61–1.24 (m,
8 H).
13C NMR (126 MHz):  = 207.1 (C=O), 146.8, 143.1, 138.0, 132.6, 132.0,
130.6, 129.7, 129.3, 128.8, 127.9, 126.3, 124.7, 124.2, 122.9, 121.5,
121.4, 97.0, 96.7, 86.0, 78.1, 66.1, 51.4, 46.8, 30.3, 25.1, 24.4.








Obtained according to the general procedure from 1p (85 mg) and L-
pipecolic acid.
Combined yield: 39 mg; 6o/8 = 76:24; pale-brown powder; mp 168–
170 °C (decomp.).
1H NMR (400 MHz):  (6o) = 8.23 (d, J = 8.0 Hz, 1 H), 8.12 (d, J = 8.3 Hz,
1 H), 7.99–7.87 (m, 3 H), 7.70 (t, J = 7.5 Hz, 1 H), 7.65 (d, J = 6.9 Hz, 1
H), 7.12 (d, J = 9.0 Hz, 1 H), 6.66 (d, J = 2.2 Hz, 1 H), 5.92 (s, 1 H), 5.08
(s, 1 H), 4.42 (d, J = 9.5 Hz, 1 H), 2.76–1.19 (m, 8 H);  (8) = 8.64–7.60
(m, 7 H), 7.06 (d, J = 9.0 Hz, 1 H), 6.74 (d, J = 2.2 Hz, 1 H), 5.25 (s, 1 H),
4.50 (d, J = 10.2 Hz, 1 H), 2.76–1.19 (m, 8 H).
13C NMR (126 MHz):  (6o) = 207.9, 157.0, 143.3, 142.8, 137.5, 133.1,
131.9, 130.9, 129.7, 128.9, 126.8, 124.5, 122.7, 121.5, 121.3, 120.1,
118.5, 96.5, 95.9, 85.8, 78.2, 66.4, 51.8, 47.0, 30.7, 25.1, 24.8;  (8) =
206.1, 154.6, 143.4, 142.6, 141.9, 135.9, 132.8, 131.6, 130.8, 129.5,
128.8, 126.9, 124.9, 122.9, 121.2 (2C), 118.5, 117.6, 116.0, 95.8, 79.0,
67.5, 51.6, 47.0, 29.8, 25.1, 24.4.
HRMS (ESI): m/z [M + H]+ calcd for C27H21Cl3N3O6: 588.0490; found:
588.0494 (6o).





Obtained according to the general procedure from 1a (61 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 71 mg (52%); pale-yellow powder; mp 239–240 °C (decomp.).
IR (ATR): 1702, 1607, 1556, 1490, 1442, 1436, 1403, 1346, 1333 cm–1.
1H NMR (400 MHz):  = 8.26 (dd, J = 8.2, 1.0 Hz, 1 H), 8.08 (d, J = 8.2
Hz, 1 H), 7.95 (d, J = 6.8 Hz, 1 H), 7.87 (dd, J = 8.2, 7.2 Hz, 1 H), 7.97–
7.72 (m, 2 H), 7.21–6.94 (m, 5 H), 6.72 (d, J = 7.6 Hz, 1 H), 6.38–6.32
(m, 1 H), 5.79 (q, J = 6.5 Hz, 1 H), 5.75 (d, J = 7.9 Hz, 1 H), 5.38 (s, 1 H),
4.42 (dd, J = 11.1, 2.9 Hz, 1 H), 3.67 (d, J = 14.5 Hz, 1 H), 3.47 (d, J = 14.5
Hz, 1 H), 3.29 (dd, J = 15.2, 2.9 Hz, 1 H), 2.81 (dd, J = 15.2, 11.1 Hz, 1 H).
19F NMR (376 MHz):  = 94.2 (d, J = 6.5 Hz, CF3).
13C NMR (126 MHz):  = 208.3 (C=O), 153.0, 143.3, 137.9, 132.8 (2C),
132.7, 132.3, 130.8, 129.7, 129.6, 128.9, 128.87, 126.8, 126.6, 126.44,
126.41, 126.3, 123.2 (q, J = 281.3 Hz, CF3), 123.1, 121.5 (2C), 117.7,
117.3, 95.8, 78.3, 77.4 (q, J = 34.0 Hz, C-6′), 61.7, 51.0, 48.5, 33.5.






Obtained according to the general procedure from 1b (65 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 99 mg (71%); yellow powder; mp 226–227 °C (decomp.).
IR (ATR): 1700, 1603, 1587, 1559, 1488, 1438, 1421, 1403, 1336 cm–1.
1H NMR (500 MHz):  = 8.25 (d, J = 7.8 Hz, 1 H), 8.09 (d, J = 8.3 Hz, 1
H), 7.98 (d, J = 6.9 Hz, 1 H), 7.88 (dd, J = 8.3, 7.2 Hz, 1 H), 7.78–7.71 (m,
2 H), 7.19–7.03 (m, 3 H), 6.83 (d, J = 8.3 Hz, 1 H), 6.76 (dd, J = 8.3, 1.2
Hz, 1 H), 6.73 (d, J = 7.7 Hz, 1 H), 5.70 (q, J = 6.6 Hz, 1 H), 5.44 (d, J = 1.2
Hz, 1 H), 5.31 (s, 1 H), 4.43 (dd, J = 11.2, 2.8 Hz, 1 H), 3.70 (d, J = 14.4
Hz, 1 H), 3.52 (d, J = 14.4 Hz, 1 H), 3.29 (dd, J = 15.2, 2.8 Hz, 1 H), 2.81
(dd, J = 15.2, 11.2 Hz, 1 H), 1.55 (s, 3 H, Me).
19F NMR (376 MHz):  = 94.2 (d, J = 6.6 Hz, CF3).
13C NMR (126 MHz):  = 208.4 (C=O), 150.9, 143.3, 138.0, 132.9, 132.8,
132.6, 132.4, 132.3, 130.7, 129.7, 129.61, 129.56, 128.8, 127.0, 126.8,
126.4, 126.28, 126.26, 123.2 (q, J = 281.4 Hz, CF3), 121.4, 121.3, 117.3,
116.9, 95.7, 78.4, 77.5 (q, J = 33.8 Hz, C-6′), 61.7, 51.2, 48.5, 33.5, 20.3.






Obtained according to the general procedure from 1c (69 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 90 mg (63%); yellow powder; mp 201–202 °C (decomp.).
IR (ATR): 1704, 1607, 1556, 1431, 1408, 1337 cm–1.
1H NMR (400 MHz):  = 8.27–8.21 (m, 1 H), 8.06 (d, J = 8.2 Hz, 1 H),
7.97 (d, J = 7.1 Hz, 1 H), 7.88 (dd, J = 8.2, 7.1 Hz, 1 H), 7.80–7.74 (m, 2
H), 7.19–7.12 (m, 2 H), 7.09–7.03 (m, 1 H), 6.87 (d, J = 9.0 Hz, 1 H),
6.73 (d, J = 7.6 Hz, 1 H), 6.53 (dd, J = 9.0, 2.9 Hz, 1 H), 5.65 (q, J = 6.6 Hz,
1 H), 5.34 (s, 1 H), 5.17 (d, J = 2.9 Hz, 1 H), 4.44 (dd, J = 11.3, 3.1 Hz, 1
H), 3.71 (d, J = 14.3 Hz, 1 H), 3.54 (d, J = 14.3 Hz, 1 H), 3.29 (dd, J = 15.4,
3.1 Hz, 1 H), 2.80 (dd, J = 15.4, 11.3 Hz, 1 H), 2.72 (s, 3 H).
19F NMR (376 MHz):  = 94.2 (d, J = 6.6 Hz, CF3).
13C NMR (126 MHz):  = 208.2 (C=O), 154.8, 147.0, 143.3, 138.0, 132.8,
132.7, 132.5, 132.4, 130.7, 129.8, 129.6, 129.0, 126.8, 126.4, 126.29,
126.25, 123.2 (q, J = 281.2 Hz, CF3), 121.6 (2C), 118.7, 117.6, 116.7,
109.3, 95.7, 78.3, 77.5 (q, J = 33.8 Hz, C-6′), 61.7, 54.6, 51.5, 48.5, 33.5.






Obtained according to the general procedure from 1d (72 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 94 mg (64%); pale-yellow powder; mp 226–227 °C (decomp.).
IR (ATR): 1698, 1605, 1585, 1557, 1487, 1471, 1436, 1405, 1337 cm–1.
1H NMR (400 MHz):  = 8.27 (d, J = 7.8 Hz, 1 H), 8.07 (d, J = 8.3 Hz, 1
H), 7.95 (d, J = 6.7 Hz, 1 H), 7.86 (t, J = 7.8 Hz, 1 H), 7.79–7.70 (m, 3 H),
7.19–7.10 (m, 2 H), 7.05 (t, J = 7.2 Hz, 1 H), 6.71 (d, J = 8.0 Hz, 1 H),SynOpen 2021, 5, 1–16
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5.39 (s, 1 H), 5.34 (d, J = 8.0 Hz, 1 H), 4.43 (dd, J = 11.2, 2.5 Hz, 1 H),
4.03–3.94 (m, 2 H), 3.66 (d, J = 14.4 Hz, 1 H), 3.45 (d, J = 14.4 Hz, 1 H),
3.29 (dd, J = 15.3, 2.5 Hz, 1 H), 2.79 (dd, J = 15.3, 11.2 Hz, 1 H), 1.39 (t,
J = 6.9 Hz, 3 H).
19F NMR (376 MHz):  = 94.5 (d, J = 6.6 Hz, CF3).
13C NMR (126 MHz):  = 208.9 (C=O), 148.3, 143.5, 143.3, 138.0, 132.8,
132.7, 132.3, 130.8, 129.7, 129.6, 128.8, 128.6, 126.8, 126.38, 126.35,
126.2, 123.2 (q, J = 281.4 Hz, CF3), 122.8, 122.2, 121.5, 121.3, 118.1,
113.5, 95.9, 78.3, 77.6 (q, J = 33.8 Hz, C-6′), 65.3, 61.6, 51.0, 48.4, 33.4,
14.9.






Obtained according to the general procedure from 1e (70 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 89 mg (62%); pale-yellow powder; mp 240–241 °C (decomp.).
IR (ATR): 1703, 1605, 1557, 1482, 1435, 1415, 1404, 1344, 1333 cm–1.
1H NMR (500 MHz):  = 8.29 (d, J = 7.6 Hz, 1 H), 8.11 (d, J = 8.2 Hz, 1
H), 7.94 (d, J = 6.9 Hz, 1 H), 7.89 (t, J = 7.7 Hz, 1 H), 7.82–7.74 (m, 2 H),
7.19–7.12 (m, 2 H), 7.06 (t, J = 7.8 Hz, 1 H), 6.95 (dd, J = 8.8, 2.1 Hz, 1
H), 6.90 (d, J = 8.8 Hz, 1 H), 6.73 (d, J = 7.7 Hz, 1 H), 5.77 (q, J = 6.3 Hz,
1 H), 5.64 (d, J = 2.1 Hz, 1 H), 5.29 (s, 1 H), 4.43 (dd, J = 11.2, 2.6 Hz, 1
H), 3.69 (d, J = 14.5 Hz, 1 H), 3.51 (d, J = 14.5 Hz, 1 H), 3.29 (dd, J = 15.2,
2.6 Hz, 1 H), 2.81 (dd, J = 15.2, 11.2 Hz, 1 H).
19F NMR (376 MHz):  = 94.1 (d, J = 6.3 Hz, CF3).
13C NMR (126 MHz):  = 208.2 (C=O), 151.5, 143.3, 137.2, 133.1, 132.7,
132.6, 132.0, 130.7, 129.7, 129.6, 129.1, 129.0, 128.1, 126.8, 126.7,
126.6, 126.5, 126.3, 122.0 (q, J = 281.5 Hz, CF3), 121.7, 121.5, 119.1,
118.9, 95.1, 78.2, 77.4 (q, J = 34.0 Hz, C-6′), 61.7, 50.8, 48.5, 33.5.






Obtained according to the general procedure from 1f (79 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 104 mg (68%); pale-yellow powder; mp 184–185 °C (decomp.).
IR (ATR): 1699, 1606, 1564, 1495, 1460, 1435, 1411, 1335 cm–1.
1H NMR (500 MHz):  = 8.29 (d, J = 7.3 Hz, 1 H), 8.12 (d, J = 8.3 Hz, 1
H), 7.94 (d, J = 6.8 Hz, 1 H), 7.89 (t, J = 7.5 Hz, 1 H), 7.84–7.75 (m, 2 H),
7.20–7.03 (m, 4 H), 6.73 (d, J = 7.6 Hz, 1 H), 5.81 (q, J = 6.4 Hz, 1 H),
5.57 (s, 1 H), 5.30 (s, 1 H), 4.44 (dd, J = 11.4, 2.5 Hz, 1 H), 3.69 (d, J =
14.4 Hz, 1 H), 3.51 (d, J = 14.4 Hz, 1 H), 3.30 (dd, J = 15.2, 2.5 Hz, 1 H),
2.81 (dd, J = 15.2, 11.4 Hz, 1 H).
19F NMR (376 MHz):  = 94.1 (d, J = 6.4 Hz, CF3).
13C NMR (126 MHz):  = 208.0 (C=O), 147.7, 143.3, 136.9, 133.2,
132.50, 132.45, 131.9, 130.8, 129.8, 129.61, 129.55, 129.1, 128.0,
126.90, 126.85, 126.5, 126.3, 125.0, 124.1, 122.8 (q, J = 281.7 Hz, CF3),
121.9, 121.6, 120.4, 95.0, 78.2, 77.4 (q, J = 34.6 Hz, C-6′), 61.7, 50.9,
48.5, 33.4.






Obtained according to the general procedure from 1f (92 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 96 mg (58%); yellow powder; mp 183–184 °C (decomp.).
IR (ATR): 1705, 1607, 1562, 1482, 1473, 1429, 1396, 1336 cm–1.
1H NMR (400 MHz):  = 8.27 (d, J = 7.6 Hz, 1 H), 8.10 (d, J = 8.3 Hz, 1
H), 7.93 (d, J = 6.8 Hz, 1 H), 7.87 (t, J = 7.5 Hz, 1 H), 7.82–7.72 (m, 2 H),
7.20–7.11 (m, 2 H), 7.06 (t, J = 7.0 Hz, 1 H), 6.72 (d, J = 7.6 Hz, 1 H),
6.67 (s, 1 H), 5.71 (q, J = 6.0 Hz, 1 H), 5.36 (s, 1 H), 5.28 (s, 1 H), 4.44
(dd, J = 11.6, 2.6 Hz, 1 H), 4.02–3.90 (m, 2 H), 3.69 (d, J = 14.4 Hz, 1 H),
3.51 (d, J = 14.4 Hz, 1 H), 3.29 (dd, J = 14.8, 2.6 Hz, 1 H), 2.79 (dd, J =
14.8, 11.6 Hz, 1 H), 1.39 (t, J = 6.9 Hz, 3 H).
19F NMR (376 MHz):  = 94.4 (d, J = 6.0 Hz, CF3).
13C NMR (126 MHz):  = 208.1 (C=O), 148.9, 143.2, 142.4, 137.3, 133.0,
132.63, 132.61, 132.1, 130.7, 129.7, 129.6, 128.9, 126.8, 126.6, 126.4,
126.3, 123.0 (q, J = 281.9 Hz, CF3), 121.6, 121.5, 120.8, 120.0, 116.2,
115.1, 95.3, 78.3, 65.4, 61.7, 50.7, 48.5, 33.4, 14.7 (the signal of the C-
6′ carbon atom overlaps with the signal of CDCl3).





Obtained according to the general procedure from 1h (73 mg) and (S)-
1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid.
Yield: 70 mg (48%); yellow powder; mp 232–233 °C (decomp.).
IR (ATR): 1706, 1607, 1587, 1557, 1525, 1494, 1486, 1450, 1432, 1398,
1346, 1339 cm–1.
1H NMR (400 MHz):  = 8.31 (d, J = 8.0 Hz, 1 H), 8.18 (d, J = 8.2 Hz, 1
H), 8.02–7.69 (m, 5 H), 7.21–7.07 (m, 4 H), 6.76 (d, J = 6.7 Hz, 1 H),
6.60 (d, J = 2.5 Hz, 1 H), 5.90 (q, J = 6.2 Hz, 1 H), 5.32 (s, 1 H), 4.47 (dd,
J = 11.3, 2.9 Hz, 1 H), 3.74 (d, J = 14.5 Hz, 1 H), 3.59 (d, J = 14.5 Hz, 1 H),
3.33 (dd, J = 15.5, 2.9 Hz, 1 H), 2.86 (dd, J = 15.5, 11.3 Hz, 1 H).
19F NMR (376 MHz):  = 93.9 (d, J = 6.2 Hz, CF3).
13C NMR (126 MHz):  = 208.3 (C=O), 157.3, 143.4, 142.9, 136.5, 133.6,
132.50, 132.45, 131.8, 131.0, 129.8, 129.6, 129.1, 127.2, 126.9, 126.6,
126.3, 124.7, 123.1, 122.7 (q, J = 281.9 Hz, CF3), 121.9, 121.6, 118.6,
118.2, 94.4, 78.2, 77.6 (q, J = 34.4 Hz, C-6′), 61.9, 50.9, 48.5, 33.5.
HRMS (ESI): m/z [M + H]+ calcd for C31H21F3N3O6: 588.1377; found:
588.1380.
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